Patents by Inventor Liqi He

Liqi He has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
    Publication number: 20230144824
    Abstract: Compounds according to formula I or II are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: May 11, 2023
    Inventors: Liqi HE, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Qiang CONG, Yam B. POUDEL, Prasanna SIVAPRAKASAM, Christine M. TARBY, Patrice GILL, Andrew F. DONNELL, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
  • 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
    Publication number: 20230140430
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: May 4, 2023
    Inventors: Matthew COX, Liqi HE, Sanjeev GANGWAR, Ashvinikumar V. GAVAI, Matthias BROEKEMA, Qiang CONG, Daniel O'MALLEY, Yam B. POUDEL, Christine M. TARBY
  • 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS AND METHODS AND USES THEREFOR
    Publication number: 20230140047
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: December 14, 2022
    Publication date: May 4, 2023
    Inventors: YAM B. POUDEL, Sanjeev GANGWAR, Liqi HE, Prasanna SIVAPRAKASAM, Matthias BROEKEMA, Matthew COX, Christine M. TARBY, Qian ZHANG, Naidu S. CHOWDARI
  • 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
    Publication number: 20230130516
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: April 27, 2023
    Inventors: Qian ZHANG, Sanjeev GANGWAR, Ashvinikumar V. GAVAI, Qiang CONG, Yam B. POUDEL, Liqi HE, Prasanna SIVAPRAKASAM, Christine M. TARBY
  • 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
    Publication number: 20230122249
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). (I) Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: April 20, 2023
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Yam B. POUDEL, Matthew COX, Liqi HE, Daniel O'MALLEY, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Matthias BROEKEMA, Prasanna SIVAPRAKASAM, Christine M. TARBY, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH,Murugaiah
  • 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
    Publication number: 20230041738
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). (I) Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Application
    Filed: January 26, 2021
    Publication date: February 9, 2023
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Yam B. POUDEL, Matthew COX, Liqi HE, Ashvinikumar V. GAVAI, Sanjeev GANGWAR, Mathias BROEKEMA, Christine M. TARBY, Murugaiah ANDAPPAN MURUGAIAH SUBBAIAH
  • 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
    Patent number: 11554120
    Abstract: Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: January 17, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yam B. Poudel, Sanjeev Gangwar, Liqi He, Prasanna Sivaprakasam, Matthias Broekema, Matthew Cox, Christine M. Tarby, Qian Zhang, Naidu S. Chowdari
  • Macrocyclic toll-like receptor 7 (TLR7) agonists
    Patent number: 11485741
    Abstract: Compounds having a structure according to formula are modulators of TLR7 activity and can be used to treat conditions amenable to treatment by the modulation of TLR7 activity.
    Type: Grant
    Filed: April 23, 2019
    Date of Patent: November 1, 2022
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ashok V. Purandare, Honghe Wan, Liqi He, Sanjeev Gangwar, Shoshana L. Posy, Yam B. Poudel, Prasanna Sivaprakasam, Naidu S. Chowdari
  • 2H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
    Patent number: 11400094
    Abstract: Compounds according to formula II are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: August 2, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yam B. Poudel, Sanjeev Gangwar, Liqi He, Prasanna Sivaprakasam
  • MACROCYCLIC TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
    Publication number: 20210053979
    Abstract: Compounds having a structure according to formula are modulators of TLR7 activity and can be used to treat conditions amenable to treatment by the modulation of TLR7 activity.
    Type: Application
    Filed: April 23, 2019
    Publication date: February 25, 2021
    Inventors: Ashok V. PURANDARE, Honghe WAN, Liqi HE, Sanjeev GANGWAR, Shoshana L. POSY, Yam B. POUDEL, Prasanna SIVAPRAKASAM, Naidu S. CHOWDARI
  • Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
    Patent number: 10927114
    Abstract: Compounds having a structure according to formula (I) or (II) where R1, R2, and Ar are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: February 23, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Liqi He, Sanjeev Gangwar, Shoshana L. Posy, Yam B. Poudel, Prasanna Sivaprakasam
  • Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
    Patent number: 10919895
    Abstract: Compounds having a structure according to formula (I) where R1 and Ar are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: February 16, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yam B. Poudel, Liqi He, Sanjeev Gangwar, Shoshana L. Posy, Prasanna Sivaprakasam
  • Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
    Patent number: 10913741
    Abstract: Compounds having a structure according to formula (I) or (II) where R1, R2, R1, R4, Ar and X1 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: February 9, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Liqi He, Sanjeev Gangwar, Yam B. Poudel, Prasanna Sivaprakasam
  • TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING HETEROATOM-LINKED AROMATIC MOIETIES, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR
    Publication number: 20200392137
    Abstract: Compounds having a structure according to formula (I) or (II) where R1, R2, R3, R4, Ar and X1 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
    Type: Application
    Filed: August 26, 2020
    Publication date: December 17, 2020
    Inventors: Liqi HE, Sanjeev Gangwar, Yam B. Poudel, Prasanna Sivaprakasam
  • TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING A HETEROBIARYL MOIETY, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR
    Publication number: 20200317672
    Abstract: Compounds having a structure according to formula (I) or (II) where R1, R2, and Ar are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
    Type: Application
    Filed: June 17, 2020
    Publication date: October 8, 2020
    Inventors: Liqi HE, Sanjeev GANGWAR, Shoshana L. POSY, Yam B. POUDEL, Prasanna SIVAPRAKASAM
  • Toll-like receptor 7 (TLR7) agonists having heteroatom-linked aromatic moieties, conjugates thereof, and methods and uses therefor
    Patent number: 10793569
    Abstract: Compounds having a structure according to formula (I) or (II) where R1, R2, R3, R4, Ar and X1 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: October 6, 2020
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Liqi He, Sanjeev Gangwar, Yam B. Poudel, Prasanna Sivaprakasam
  • TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING A PYRIDINE OR PYRAZINE MOIETY, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR
    Publication number: 20200308175
    Abstract: Compounds having a structure according to formula (I) where R1 and Ar are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Inventors: Yam B. POUDEL, Liqi HE, Sanjeev GANGWAR, Shoshana L. POSY, Prasanna SIVAPRAKASAM
  • TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS HAVING HETEROATOM-LINKED AROMATIC MOIETIES, CONJUGATES THEREOF, AND METHODS AND USES THEREFOR
    Publication number: 20200255429
    Abstract: Compounds having a structure according to formula (I) or (II) where R1, R2, R3, R4, Ar and X1 are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
    Type: Application
    Filed: May 1, 2020
    Publication date: August 13, 2020
    Inventors: Liqi HE, Sanjeev GANGWAR, Yam B. POUDEL, Prasanna SIVAPRAKASAM
  • Toll-like receptor 7 (TLR7) agonists having a pyridine or pyrazine moiety, conjugates thereof, and methods and uses therefor
    Patent number: 10723736
    Abstract: Compounds having a structure according to formula (I) where R1 and Ar are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: July 28, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yam B. Poudel, Liqi He, Sanjeev Gangwar, Shoshana L. Posy, Prasanna Sivaprakasam
  • Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
    Patent number: 10711003
    Abstract: Compounds having a structure according to formula (I) or (II) where R1, R2, and Ar are as defined herein, are agonists for the Toll-like receptor 7 (TLR7) and can be used as adjuvants for stimulating the immune system. Some such compounds can be used in conjugates for targeted delivery to the organ or tissue of intended action.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: July 14, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Liqi He, Sanjeev Gangwar, Shoshana L. Posy, Yam B. Poudel, Prasanna Sivaprakasam